Vaccination of stage III/IV melanoma patients with long NY-ESO-1 peptide and CpG-B elicits robust CD8+ and CD4+ T-cell responses with multiple specificities including a novel DR7-restricted epitope

P. Baumgaertner, C. Costa Nunes, A. Cachot, H. Maby-El Hajjami, L. Cagnon, M. Braun, L. Derré, J. P. Rivals, D. Rimoldi, S. Gnjatic, S. Abed Maillard, P. Marcos Mondéjar, M. P. Protti, E. Romano, O. Michielin, P. Romero, D. E. Speiser, C. Jandus

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Vaccination of stage III/IV melanoma patients with long NY-ESO-1 peptide and CpG-B elicits robust CD8+ and CD4+ T-cell responses with multiple specificities including a novel DR7-restricted epitope'. Together they form a unique fingerprint.

Medicine & Life Sciences